Evaluation of miR-186-5p in publicly available datasets demonstrated lower expression of miR-186 in high-risk and MYCN amplified neuroblastoma and correlated with expression of NK activation markers, NKG2D and DNAM-1. The gene discussed is MYCN; the disease is neuroblastoma.